Curcumin and Retinal Study

Part of paid clinical trials in Lubbock, Texas.

Sponsor
Texas Tech University Health Sciences Center
Study ID
NCT05774704
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Bioavailability
  • Gut Microbiome
  • Safety

Eligibility Criteria

Sex
ALL
Age
40 Years - 89 Years
Healthy Volunteers
Accepted

Interventions

  • Low curcumin group — DRUG
    One curcumin capsule (250 mg curcumin) after each meal, 3 times a day for 2 weeks.
  • High curcumin group — DRUG
    One curcumin capsule (500 mg curcumin) after each meal, 3 times a day for 2 weeks.

Study Details

To test how two weeks of curcumin supplementation would cross the blood brain barrier (BBB) and attach to amyloid beta proteins, to assess the feasibility (safety and bioavailability), and to explore the resulting abundance/composition of gut microbiota.

Key Dates

Start date
Aug 21, 2023
Status verified
Jan 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Active Comparator: Low curcumin group
  • Active Comparator: High curcumin group

Primary Outcome Measure

Retinal imaging- amyloid fluorescent intensity [ Time Frame: Baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Texas Tech University Health Sciences CenterLubbockTexas79430
Chwan-Li (Leslie) Shen, PhD
[email protected]
806-743-2815
Chwan-Li (Leslie) Shen, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Lubbock, TX

By research site
Texas Tech University Health Sciences Center· Lubbock, TX

Related Studies